A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Mellado, B
Font, A
Carles, J
Catalán, G
Larriba, JLG
Gallardo, E
Fernández, LA
Nogué, M
Lianes, P
Del Alba, AG
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Univ Barcelona, Hosp Germans Trias & Pujol, Barcelona, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Hosp Son Liatzer, Islas Baleares, Spain
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Corp Sanitaria Parc Tauli, Barcelona, Spain
[7] Hosp Terrassa, Barcelona, Spain
[8] Hosp Gen Vic, Barcelona, Spain
[9] Hosp Mataro, Barcelona, Spain
[10] Hosp Son Dureta, Islas Baleares, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：434S / 434S
页数：1
相关论文
共 50 条
  • [41] Phase I study of epirubicin plus docetaxel (ET) in patients (pts) with hormone refractory prostate cancer (HRPC).
    Henary, H
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 448S - 448S
  • [42] Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial
    Caffo, O.
    Sava, T.
    Comploj, E.
    Giampaolo, M.
    Zustovich, F.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    Valduga, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [44] Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)
    Hudes, GR
    Celano, P
    Torti, F
    Tabatabai, A
    Murgo, A
    Hussain, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 431S - 431S
  • [45] Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer
    Yasufuku, Tomihiko
    Shigemura, Katsumi
    Matsumoto, Osamu
    Arakawa, Soichi
    Fujisawa, Masato
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (03) : 200 - 205
  • [46] Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    DeJager, R.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H. B.
    Earhart, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [47] A phase II study of estramustine (E), docetaxel (D) and exisulind in hormonerefractory prostate cancer (HRPC): Initial results of CALGB 90004.
    Dawson, NA
    Halabi, S
    Biggs, DD
    Ou, SS
    Kelly, WK
    Small, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 415S - 415S
  • [48] High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.
    Kasimis, B
    Cogswell, J
    Hwang, S
    Chang, VT
    Srinivas, S
    Zhong, F
    Duque, L
    Morales, E
    Boholli, I
    Blumenfrucht, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 428S - 428S
  • [49] Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer
    Nelius, T
    Reiher, F
    Lindenmeir, T
    Klatte, T
    Rau, O
    Burandt, J
    Filleur, S
    Allhoff, EP
    ONKOLOGIE, 2005, 28 (11): : 573 - 578
  • [50] Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
    L Galli
    A Fontana
    C Galli
    L Landi
    E Fontana
    A Antonuzzo
    M Andreuccetti
    E Aitini
    R Barbieri
    R Di Marsico
    A Falcone
    British Journal of Cancer, 2007, 97 : 1613 - 1617
12345